Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-wzw2p Total loading time: 0 Render date: 2024-06-07T19:38:47.960Z Has data issue: false hasContentIssue false

Chapter 8 - Basket Trials and Umbrella Trials

from Part III - Basic Ingredients for Master Protocols

Published online by Cambridge University Press:  20 March 2023

Jay J. H. Park ,
Edward J. Mills  and
J. Kyle Wathen
By
Jay J. H. Park ,
Edward J. Mills  and
J. Kyle Wathen
Jay J. H. Park
Affiliation:
McMaster University, Ontario
Edward J. Mills
Affiliation:
McMaster University, Ontario
J. Kyle Wathen
Affiliation:
Cytel, Cambridge, Massachusetts
Get access

Summary

This chapter discusses characteristics of basket and umbrella trials and their key design considerations. Basket trials refer to clinical trials conducted to test one or more targeted therapies on multiple diseases that share common molecular alternations or other predictive risk factors. Umbrella trials refer to clinical trials that test two or more targeted therapies for a single disease that is stratified into multiple groups. In addition to sample size and randomisation considerations that are important to all clinical trials, specific design considerations that are important for basket and umbrella trials include: biological plausibility of targeted intervention(s), accuracy of biomarker assays, biospecimen collection procedures, and prevalence of targeted biomarker.

Keywords

basket trialsumbrella trialsprecision medicineprecison oncology
Type
Chapter
Information
Introduction to Adaptive Trial Designs and Master Protocols , pp. 87 - 100
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Heckman-Stoddard, BM, Smith, JJ. Precision medicine clinical trials: defining new treatment strategies. Semin Oncol Nurs. 2014;30(2):109–16.CrossRefGoogle Scholar
Berry, DA. The brave new world of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research. Mol Oncol. 2015;9(5):951–9.Google Scholar
Antoniou, M, Jorgensen, AL, Kolamunnage-Dona, R. Biomarker-guided adaptive trial designs in phase II and phase III: a methodological review. PloS ONE. 2016;11(2):e0149803.Google Scholar
Antoniou, M, Kolamunnage-Dona, R, Jorgensen, AL. Biomarker-guided non-adaptive trial designs in phase II and phase III: a methodological review. J Pers Med. 2017;7(1).Google Scholar
Kumar-Sinha, C, Chinnaiyan, AM. Precision oncology in the age of integrative genomics. Nat Biotechnol. 2018;36(1):46–60.CrossRefGoogle ScholarPubMed
Abrams, J, Conley, B, Mooney, M, et al. National Cancer Institute’s Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book. 2014:71–6.Google Scholar
Collins, FS, Varmus, H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–5.Google Scholar
Ashley, EA. The precision medicine initiative: a new national effort. JAMA. 2015;313(21):2119–20.Google Scholar
Ashley, EA. Towards precision medicine. Nat Rev Genet. 2016;17(9):507–22.Google Scholar
Woodcock, J, LaVange, LM. Master protocols to study multiple therapies, multiple diseases, or both. N Eng J Med 2017;377(1):62–70.Google Scholar
U.S. Department of Health and Human Services, Food and Drug Administration. Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry (Draft Guidance). U.S. Department of Health and Human Services; 2018. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM621817.pdf.Google Scholar
Park, JJH, Siden, E, Zoratti, MJ, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials. 2019;20(1):572.Google Scholar
Siden, EG, Park, JJ, Zoratti, MJ, et al. Reporting of master protocols towards a standardized approach: a systematic review. Contemp Clin Trials Commun. 2019;15:100406.Google Scholar
Hirakawa, A, Asano, J, Sato, H, Teramukai, S. Master protocol trials in oncology: review and new trial designs. Contemp Clin Trials Commun. 2018;12:1–8.Google Scholar
Lam, VK, Papadimitrakopoulou, V. Master protocols in lung cancer: experience from Lung Master Protocol. Curr Opin Oncol. 2018;30(2):92–7.Google Scholar
Ledford, H. ‘Master protocol’ aims to revamp cancer trials: pilot project will bring drug companies together to test targeted lung-cancer therapies. Nature. 2013;498(7453):146–8.Google Scholar
Redman, MW, Allegra, CJ. The master protocol concept. Semin Oncol. 2015;42(5):724–30.CrossRefGoogle ScholarPubMed
Renfro, LA, Sargent, DJ. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann Oncol. 2017;28(1):34–43.CrossRefGoogle ScholarPubMed
Parmar, MK, Sydes, MR, Cafferty, FH, et al. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: multi-arm, multi-stage platform, umbrella and basket protocols. Clin Trials. 2017;14(5):451–61.CrossRefGoogle ScholarPubMed
De Benedetti, F, Gattorno, M, Anton, J, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med. 2018;378(20):1908–19.Google Scholar
Muhlbacher, J, Jilma, B, Wahrmann, M, et al. Blockade of HLA antibody-triggered classical complement activation in sera from subjects dosed with the anti-C1s monoclonal antibody TNT009 – results from a randomized first-in-human phase 1 trial. Transplantation. 2017;101(10):2410–18.Google Scholar
The ASCO Post. 2018 ASCO: IMPACT Trial matches treatment to genetic changes in the tumor to improve survival across multiple cancer types. 2018. www.ascopost.com/News/58897Google Scholar
Le Tourneau, C, Delord, JP, Goncalves, A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324–34.Google Scholar
Pon, JR, Marra, MA. Driver and passenger mutations in cancer. Annu Rev Pathol. 2015;10:25–50.Google Scholar
Brown, AL, Li, M, Goncearenco, A, Panchenko, AR. Finding driver mutations in cancer: elucidating the role of background mutational processes. PLoS Comput Biol. 2019;15(4):e1006981.CrossRefGoogle ScholarPubMed
Park, JJ, Harari, O, Dron, L, Mills, EJ, Thorlund, K. Effects of biomarker diagnostic accuracy on biomarker-guided phase 2 trials. Contemp Clin Trials Commun. 2019;15:100396.CrossRefGoogle ScholarPubMed
Bubendorf, L, Lantuejoul, S, de Langen, AJ, Thunnissen, E. Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: number 2 in the series ‘Pathology for the Clinician’ edited by Peter Dorfmuller and Alberto Cavazza. Eur Respir Rev. 2017;26(144).Google Scholar
Iding, JS, Krimsky, W, Browning, R. Tissue requirements in lung cancer diagnosis for tumor heterogeneity, mutational analysis and targeted therapies: initial experience with intra-operative Frozen Section Evaluation (FROSE) in bronchoscopic biopsies. J Thorac Dis. 2016;8(Suppl 6):S488–S93.Google Scholar
Arneth, B. Update on the types and usage of liquid biopsies in the clinical setting: a systematic review. BMC Cancer. 2018 Dec;18(1):1–2.Google Scholar
Heitzer, E, Ulz, P, Geigl, JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61(1):112–23.Google Scholar
Huang, GD, Bull, J, Johnston McKee, K, et al. Clinical trials recruitment planning: a proposed framework from the Clinical Trials Transformation Initiative. Contemp Clin Trials. 2018;66:74–9.Google Scholar
Brown, SR, Gregory, WM, Twelves, CJ, et al. Designing phase II trials in cancer: a systematic review and guidance. Br J Cancer. 2011;105(2):194–9.Google Scholar
Simon, R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1–10.Google Scholar
Clark, GM, Zborowski, DM, Culbertson, JL, et al. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J Thorac Oncol. 2006;1(8):837–46.Google Scholar
Clark, GM. Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib. Mol Oncol. 2008;1(4):406–12.Google Scholar
Friedman, LM, Furberg, C, DeMets, DL, Reboussin, D, Granger, CB. Fundamentals of Clinical Trials: Springer; 2015.Google Scholar
Cartwright, N. What are randomised controlled trials good for? Phil Stud. 2010;147(1):59.Google Scholar
Roberts, C, Torgerson, DJ. Understanding controlled trials: baseline imbalance in randomised controlled trials. BMJ. 1999;319(7203):185.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×